首页> 美国卫生研究院文献>Nature and Science of Sleep >New approaches in the treatment of short term and middle of the night insomnia: emerging evidence for a role for sublingual zolpidem tablets
【2h】

New approaches in the treatment of short term and middle of the night insomnia: emerging evidence for a role for sublingual zolpidem tablets

机译:治疗短期和深夜失眠的新方法:舌下唑吡坦片的作用的新证据

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Insomnia affects a significant proportion of the general population and an even greater proportion of patients seen in general medical care. Insomnia has multiple negative effects on health status, decreases quality of life, and is associated with increased health care costs. Current treatments for insomnia include pharmacologic and behavioral strategies. Pharmacologic treatments may be effective for short-term and middle-of-the-night (MOTN) insomnia, but the usefulness of many sleep medications is limited by the residual daytime sedation with which they are associated. This problem is especially important in the case of MOTN insomnia, when only a few hours may elapse between the time a patient takes the medication and when he or she must rise. The development of sublingual and low-dose formulations of zolpidem raises the possibility that pharmacologic therapy may allow patients with MOTN insomnia to be effectively treated with a decreased risk of residual daytime sedation. Current studies of this strategy are promising, and several formulations are in the process of being brought to market.
机译:失眠会影响到大比例的普通人群,甚至会影响到普通医疗中更多的患者。失眠会对健康状况产生多种负面影响,降低生活质量,并增加医疗费用。当前的失眠治疗方法包括药理和行为策略。药物治疗可能对短期和半夜失眠有效,但许多睡眠药物的有效性受到与之相关的白天剩余镇静作用的限制。在MOTN失眠的情况下,这个问题尤为重要,因为从患者服药到必须复活之间只有几个小时。唑吡坦的舌下和低剂量制剂的开发增加了药理疗法可以有效治疗MOTN失眠患者的可能性,同时降低了日间残留镇静的风险。目前对该策略的研究是有前途的,并且有几种配方正在推向市场。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号